Sergio Santillana

Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC—A Randomized Phase III Trial

J. Randolph Hecht, Yung‐Jue Bang, Shukui Qin et al. · Journal of Clinical Oncology · 2015 · 621 citations · Full text

Medicine, Oncology, Pharmacology +16

Planning cancer control in Latin America and the Caribbean

Paul E. Goss, Brittany Lee, Tanja Badovinac-Črnjević et al. · The Lancet Oncology · 2013 · 504 citations · Full text

Public Health, Health Policy, Oncology +14

CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

Xavier Pivot, Alexey Manikhas, Zurawski Bogdan et al. · Journal of Clinical Oncology · 2015 · 251 citations · Full text

Medicine, Oncology, Pharmacology +17

Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31

Karen A. Gelmon, Frances Boyle, Bella Kaufman et al. · Journal of Clinical Oncology · 2015 · 183 citations · Full text

Medicine, Oncology, Pharmacology +17

Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity.

Henry Gómez, Luís Más, L. Casanova et al. · Journal of Clinical Oncology · 1998 · 155 citations

Medicine, Hematology, Oncology +17